Get the Stockscreener App
19.21
3.71%
-0.74
Avalo Therapeutics Inc stock is traded at $19.21, with a volume of 852.80K.
It is down -3.71% in the last 24 hours and up +46.64% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$19.95
Open:
$19.86
24h Volume:
852.80K
Relative Volume:
0.45
Market Cap:
$1.01B
Revenue:
$59,000
Net Income/Loss:
$-84.74M
P/E Ratio:
-3.2994
EPS:
-5.8222
Net Cash Flow:
$-59.69M
1W Performance:
+1.96%
1M Performance:
+46.64%
6M Performance:
+13.33%
1Y Performance:
+292.04%
1-Day Range:
$18.42
$20.45
1-Week Range:
$18.36
$20.65
52-Week Range:
$4.61
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
19.21 | 1.01B | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Avalo Therapeutics sets one-on-one investor meetings at Leerink Forum - Stock Titan
Millennium Group (AVTX) reports shared control of 9,857 Avalo shares (Jul 2026) - Stock Titan
AVTX Initiates Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink initiates Avalo Therapeutics stock with outperform rating By Investing.com - Investing.com Australia
Leerink Partners Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $38 - Moomoo
Leerink initiates Avalo Therapeutics stock with outperform rating - Investing.com
Avalo Therapeutics CLO Paul Varki sells $1.5m shares after option exercise - Investing.com
Certain Restricted Stock Units of Avalo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2026. - marketscreener.com
Certain Options of Avalo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2026. - marketscreener.com
AVTXAvalo Therapeutics Inc Latest SEC Filings - Finviz
AVTX News | AVALO THERAPEUTICS INC (NASDAQ:AVTX) - ChartMill
Avalo Therapeutics (AVTX) director receives fully vested options grant - Stock Titan
Avalo Therapeutics (AVTX) CMO exercises options, sells 4,654 pre-planned shares - Stock Titan
Avalo Therapeutics (AVTX) director granted fully vested options on 1,080 shares - Stock Titan
Avalo Therapeutics (AVTX) director receives grant of 1,105 stock options - Stock Titan
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Price to earnings forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Enterprise value to revenue forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to sales forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Enterprise value to EBITDA forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to book forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to sales forward of Avalo Therapeutics Inc – LSX:A3E2FR - TradingView
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index AdditionsWhat's Changed - Yahoo Finance
Avalo Therapeutics Inc Actuals & Estimates (NASDAQ:AVTX) - TradingView
Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2000 Index - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2000 Value Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Why Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Inclusion And Pipeline Progress - Sahm
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Avalo Therapeutics Edges Higher, Testing Key Resistance at $19.11MFI Oversold - dars.gov.et
Avalo Therapeutics (AVTX) Joins Russell 2000 and 3000 Indices - GuruFocus
Avalo Therapeutics added to Russell 2000 and 3000 indexes By Investing.com - Investing.com Nigeria
Avalo Therapeutics added to Russell 2000 and 3000 indexes - Investing.com
Avalo Therapeutics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
AVTX Forecast — Price Target — Prediction for 2027 - TradingView
Avalo Therapeutics CMO Mittie Doyle sells $26,100 of shares - Investing.com UK
Avalo Therapeutics CMO Mittie Doyle sells $26,100 of shares By Investing.com - Investing.com Australia
Avalo Therapeutics Inc Actuals & Estimates (FWB:C6K0) - TradingView
Form 4 Avalo Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) CMO trades 1,450 shares in 10b5-1 exercise-and-sell - Stock Titan
Avalo Therapeutics (AVTX) director awarded 40,200 stock options at $17.83 strike - Stock Titan
[Form 3] Avalo Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Avalo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Doyle Mittie - Moomoo
Avalo Therapeutics Adds Independent Director Ron Philip - The Globe and Mail
Form 8K Avalo Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):